Replies to post #29749 on Radient Pharmaceuticals Corporation fka RXPC

[GetSeriousOK]

Pharmaline knows that DR70 is off patent.

GCDx knows this, UNI knows this, Arima knows this, and CSTamdl knows this. Odd that some RXPC shareholders apparently still do not know this.


These entities are all working with DR70 without licensing it from, or paying any royalties or fees to, Radient Pharmaceuticals. This is why Radient Pharmaceuticals died and RXPC stock is now worthless. If this is still not clear, let's list Radient's "assets" and what happened to those assets:

-> DR-70: Transferred to AMDL, Inc. and now off patent, so several entities around the globe are currently trying to test/manufacture/market it.

-> CIT: declared worthless and transferred to NuVax.

-> Jade Holdings: revealed to be worthless.

-> Publications and research: CST in Hong Kong, led by Radient CEO and Officers Charter and Brown, now claims these assets as their own.

What does Radient Pharmaceuticals have left? Nothing. Well, not assets anyway. They have 5 billion shares issued and they have about $20 million in debt and they have 2.5 years of missing SEC financial filings, but those are reasons NOT to merge with Radient, and we are trying to find reasons why Arima or Provista or ANYONE would want to merge with Radient.

[guardiangel]

Radient Restructured By A Planned Reverse Merger

Jim is Correct..Pharmigene and Uni-Pharma will merge along with GCDX into the Radient Shell....GCDX is a wholly owned subsidiary of Provista Diagnostics. GCDX will operate North and South American Territories and Arima the territories listed in the Radient/AMDL Diagnostics Inc. and Uni-Pharma Agreement..That agreement ends in June 2018...The Vision of Arima is to EMERGe a/k/a Reverse Merge into Radient shell. Why Radient shell? Uni-Pharma wants full control of DR-70 and CIT...imo


http://investorshub.advfn.com/boards/read_msg.aspx?message_id=116432724

VISION

Arima drugs are expected to establish a center of the detection of cancer tumors in the next few years, tumor ablation and anticancer drugs after blood concentration monitoring systems for clinical services and patient treatment of cancer will provide more delicate and more accurate service. In view of the detection of the cancer, the efficacy of cancer treatment and cancer treatment to assess the importance of cancer treatment for as much tumor drug development.

Board Resolution Arima will be completed in 2015 in all internal protracted process review, in 2016 made public accountant unqualified opinions, 2016 public offering and listing Emerging made through 2017 by the Emerging into OTC company.

Successful public offering and listing will give Arima certain corporate social responsibility and care for the clinical needs of the mission, despite an increase in responsibility and burden, but will also strengthen the company and enhance physique to raise social awareness Arima Arima more outstanding talent to join the team. Arima will be able to face greater challenges and to assume more and more large-scale research and development and the market value of new drugs, new medical technologies, new medical devices and new diagnostic techniques of.

Arima drugs in the new wave of the future will continue to adhere to the company's rapid growth over ten years core values:
We provide our customers with the best product and patients;
Return on shareholders' equity investment;
According to Gu Huayu employees;
Arima equal treatment of partners;
To enthusiastic attitude and professional practice self connotation.

http://uni-pharma.com/about-03.html

Milestones

http://uni-pharma.com/about-02.html


Partners

http://uni-pharma.com/about-04.html